- Split View
-
Views
-
Cite
Cite
Jean-Blaise Wasserfallen, Sandrine Ostermann, Serge Leyvraz, Roger Stupp, Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death, Neuro-Oncology, Volume 7, Issue 2, April 2005, Pages 189–195, https://doi.org/10.1215/S1152851704000687
- Share Icon Share
Abstract
Effectiveness and costs of care and treatment of recurrent malignant gliomas are largely unknown. In this study, 49 patients (32 males, 17 females; mean age, 49; age range, 23-79) were treated with temozolomide (TMZ) for recurrent or progressive malignant gliomas after standard radiation therapy. Cost assessment (payer's perspective) singled out treatment for first recurrence and all costs of care until death. We computed personnel costs as wages; drugs, imaging, and laboratory tests as prices; and hospitalizations as day rates. Patients were administered a median of five TMZ cycles at recurrence. Drug acquisition costs amounted to €2206 per cycle (76% of total costs). Seven patients showed no second recurrence (two are still alive), 16 received no further chemotherapy and died after 3.9 months, and 26 received second-line chemotherapy. After the second progression, median survival was 4.0 months (95% confidence interval, 1.8-6.1). Overall monthly costs of care varied between €2450 and €3242 among the different groups, and median cost-effectiveness and cost utility ranged from€ 28,817 to €38,450 and from €41,167 to €53,369 per life of year and per quality-adjusted life-year gained, respectively. We conclude that despite high TMZ drug acquisition costs, care of recurrent malignant gliomas is comparable to other accepted therapies.
References
Bloor, K., Drummond, M.F., Brada, M., and Rampling, R. (
Brada, M., Hoang-Xuang, K., Rampling, R., Dietrich, P.Y., Dirix, L.Y., Macdonald, D., Heimans, J.J., Zonnenberg, B.A., Bravo-Marques, J.M., Henriksson, R., Stupp, R., Yue, N., Bruner, J., Dugan, M., Rao, S., and Zaknoen, S. (
Brock, C.S., Newlands, E.S., Wedge, S.R., Bower, M., Evans, H., Colquhoun, I., Roddie, M., Glaser, M., Brampton, M.H., and Rustin, G.J. (
Chamberlain, M.C., and Kormanik, P.A. (
Dinnes, J., Cave, C., Huang, S., Major, K., and Milne, R. (
Fisher, E.S., Wennberg, D.E., Stukel, T.A., Gottlieb, D.J., Lucas, F.L., and Pinder, E.L. (
Fisher, E.S., Wennberg, D.E., Stukel, T.A., Gottlieb, D.J., Lucas, F.L., and Pinder, E.L. (
Goldman, L,. Gordon, D.J., Rifkind, B.M., Hulley, S.B., Detsky, A.S., Goodman, D.W., Kinosian, B., and Weinstein, M.C. (
Guyatt, G.H., Feeny, D.H., and Patrick, D.L. (
Hillner, B.E., Agarwala, S., and Middleton, M.R. (
Karnofsky, D.A., Abelmann, W.H., Craver, L.F., and Burchenal, J.H. (
Kristiansen, K., Hagen, S., Kollevold, T., Torvik, A., Holme, I., Nesbakken, R., Hatlevoll, R., Lindgren, M., Brun, A., Lindgren, S., Notter, G., Andersen, A.P., and Elgen, K. (
Latif, A.Z., Signorini, D., Gregor, A., and Whittle, I.R. (
Levin, V.A., Silver, P., Hannigan, J., Wara, W.M., Gutin, P.H., Davis, R.L., and Wilson, C.B. (
Liu, G., Franssen, E., Fitch, M.I., and Warner, E. (
Mackworth, N., Fobair, P., and Prados, M.D. (
Middleton, M.R., Grob, J.J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M., Aamdal, S., Cebon, J., Coates, A., Dreno, B., Henz, M., Schadendorf, D., Kapp, A., Weiss, J., Fraass, U., Statkevich, P., Muller, M., and Thatcher, N. (
MRC Brain Tumour Working Party (
Osoba, D., Brada, M., Yung, W.K.A., and Prados, M. (
Osoba, D., Brada, M., Yung, W.K.A., and Prados, M.D. (
Rodriguez, L.A., and Levin, V.A. (
Silverstein, M.D., Cascino, T.L., and Harmsen, W.S. (
Stewart, L.A., Burdett, S., and Souhami, R.L. (
Stupp, R., Maeder, P., Maillard, I., Pica, A., Wurm, R., Hungerbühler, H.P., Villemure, J.G., Baumert, B., Büttner, W., de Tribolet, N., Lejeune, F., Mirimanoff, R.O., and Leyvraz, S. (
Stupp, R., Dietrich, P.Y., Ostermann Kraljevic, S., Pica, A., Maillard, I., Maeder, P., Meuli, R., Janzer, R., Pizzolato, G., Miralbell, R., Porchet, F., Regli, L., De Tribolet, N., Mirimanoff, R.O., and Leyvraz, S. (
Verger, E., Salamero, M., and Conill, C. (
Walker, M.D., Alexander, E., Jr., Hunt, W.E., MacCarty, C.S., Mahaley, M.S., Jr., Mealey, J., Jr., Norrell, H.A., Owens, G., Ransohoff, J., Wilson, C.B., Gehan, E.A., and Strike, T.A. (
Wong, E.T., Hess, K.R., Gleason, M.J., Jaeckle, K.A., Kyritsis, A.P., Prados, M.D., Levin, V.A., and Yung, W.K. (
Yung, W.K.A., Prados, M.D., Yaya-Tur, R., Rosenfeld, S.S., Brada, M., Friedman, H.S., Albright, R., Olson, J., Chang, S.M., O'Neill, A.M., Friedman, A.H., Bruner, J., Yue, N., Dugan, M., Zaknoen, S., and Levin, V.A., for the Temodal Brain Tumor Group (
Yung, W.K., Albright, R.E., Olson, J., Fredericks, R., Fink, K., Prados, M.D., Brada, M., Spence, A., Hohl, R.J., Shapiro, W., Glantz, M., Greenberg, H., Selker, R.G., Vick, N.A., Rampling, R., Friedman, H., Phillips, P., Bruner, J., Yue, N., Osoba, D., Zaknoen, S., and Levin, V.A. (
Zubrod, C.G., Schneiderman, M., Frei, E., III, Brindley, C., Gold, G.L., Shnider, B., Oviedo, R., Gorman, J., Jones, R., Jr., Jonsson, U., Colsky, J., Chalmers, T., Ferguson, B., Dederick, M., Holland, J., Selawry, O., Regelson, W., Lasagna, L., and Owens, A. (
Author notes
Health Technology Assessment Unit (J.B.W.),Multidisciplinary Oncology Centre (S.O., S.L., R.S.), Centre Hospitalier Universitaire Vaudois, University of Lausanne, CH-1011 Lausanne, Switzerland